Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY -7.89%83 EV-to-OCF is 215.47 as of Sep. 14, 2026, which is 143547% above its 10-year median of 0.15. GuruFocus rates FRA:6XY with a GF Score™ of 83/100 and a GF Value™ of €1.34 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,406 Biotechnology companies, HBM Holdings ranks worse than 98.72% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, HBM Holdings's Enterprise Value is €936.9 Mil.
HBM Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €4.3 Mil. Therefore, HBM Holdings's EV-to-OCF for today is 215.47.
The historical rank and industry rank for HBM Holdings's EV-to-OCF or its related term are showing as below:
FRA:6XY'
s EV-to-OCF Range Over the Past 10 Years
Min: -22.09 Med: 0.15 Max: 209.9
Current: 209.9
During the past 8 years, the highest EV-to-OCF of HBM Holdings was 209.90. The lowest was -22.09. And the median was 0.15.
FRA:6XY's EV-to-OCF is ranked worse than 98.72% of 1406
companies
in the Biotechnology industry
Industry Median: -3.38
vs FRA:6XY: 209.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HBM Holdings's PE Ratio (TTM) for today is calculated as:
HBM Holdings's share price for today is €1.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.095.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
HBM Holdings EV-to-OCF Related Terms
HBM Holdings EV-to-OCF Historical Data
* Premium members only.
The historical data trend for HBM Holdings's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HBM Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where HBM Holdings's EV-to-OCF falls into.
HBM Holdings's current Enterprise Value is €936.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €4.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) has a EV-to-OCF of 215.47 as of Sep. 14, 2026. This is 143547% above median its historical median of 0.15. According to the industry distribution chart, HBM Holdings ranks #1388 out of 1406 companies in the Biotechnology industry, placing it in the top 98.7%.
Is HBM Holdings' EV-to-OCF too high?
HBM Holdings' current EV-to-OCF of 215.47 is 143547% above median its 10-year median of 0.15. Based on the distribution chart, HBM Holdings ranks #1388 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HBM Holdings has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #1388 out of 1406 companies for EV-to-OCF. This places HBM Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. HBM Holdings's current EV-to-OCF is 215.47, which is 143547% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Fairly Valued. The stock's GF Value™ is €1.34, compared to a current price of €1.40 — trading 4.5% above its estimated fair value. The current EV-to-OCF is 215.47, which is 143547% above median its 10-year median of 0.15. HBM Holdings' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current EV-to-OCF is 215.47 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.40 is trading 4.5% above its estimated GF Value™ of €1.34.
GuruFocus considers HBM Holdings to be Fairly Valued.
Key valuation signals for FRA:6XY:
EV-to-OCF: 215.47 (143547% above median its 10-year median of 0.15)
GF Value™: €1.34 vs. price of €1.40 (4.5% above fair value)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
83GF Score
Get the complete analysis for FRA:6XY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
